September 12, 2016
A health ministry’s key drug review committee supported on September 9 approval of AbbVie’s anti-human TNFα monoclonal antibody Humira (adalimumab) for its use in patients with non-infectious intermediate and posterior uveitis and panuveitis who inadequately respond to existing therapies. The...read more